BiotechTube

Enhertu

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer Metastatic

Conditions

Prostate Cancer Metastatic, Prostate Cancer, CRPC

Trial Timeline

Mar 5, 2025 → Oct 1, 2028

NCT ID
NCT06610825

About Enhertu

Enhertu is a phase 2 stage product being developed by Daiichi Sankyo for Prostate Cancer Metastatic. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06610825. Target conditions include Prostate Cancer Metastatic, Prostate Cancer, CRPC.

What happened to similar drugs?

20 of 20 similar drugs in Prostate Cancer Metastatic were approved

Approved (20) Terminated (4) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved
✅LeuprolideAstellas PharmaApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06610825Phase 2Recruiting

Competing Products

20 competing products in Prostate Cancer Metastatic

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
18
PemetrexedEli LillyPhase 2
35
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
Abemaciclib + Placebo + Abiraterone acetate + PrednisoneEli LillyPhase 2/3
42
eFT508eFFECTOR TherapeuticsPhase 2
17
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
47
exatecan mesylateDaiichi SankyoPhase 2
35
PLX3397Daiichi SankyoPhase 2
27
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
29
degarelix + GoserelinAstellas PharmaPhase 3
40
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
26
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
42
YM155Astellas PharmaPhase 2
35